Rat retweeted
This is disappointing to see. Blocking access to peptides through licensed pharmacies leaves patients with fewer regulated options and risks pushing them toward unregulated sources. Patients deserve a safe, legitimate path to care..not more barriers.
Kentucky won't be the only state to block these six peptides.
HHS said it won't enforce federal law. It didn't touch state law, and pharmacy boards answer to state law.
Where states stand today:
🔴 Kentucky: blocked
🔴 Ohio: BPC-157 already not allowed
🟡 Arizona, Illinois, Massachusetts: undecided
🟢 Utah: following HHS
Most states haven't picked a side yet.
Rat retweeted
I genuinely don’t understand how the market is valuing $HIMS anymore. 😭
We’re talking about a company generating over $3 BILLION in annual revenue, yet its entire market cap is sitting around $3.7B.
That’s barely 1.2× annual sales!
And it’s not like HIMS has stopped growing.
• Q3 revenue grew 49% YoY
• Nearly 2.8 million subscribers
• Expanding internationally
• Launching new products and treatments
• Building a global consumer healthcare platform
Yes, margins have taken a hit, profitability needs improvement, and the recent earnings weren’t perfect.
But are we seriously going to ignore billions in revenue and years of growth because of a few disappointing quarters?
I’m not saying the stock can’t go lower.
I’m just struggling to understand how much more negativity the market can possibly price into this company.
$3B+ in revenue. $3.7B market cap.
Something has to give eventually.
$HIMS
They literally want you to get sick and die
Don't
Buy $HIMS and live instead
BREAKING: The American Medical Association (AMA) just asked the US government (HHS) to take back its plan to let pharmacies make BPC-157, TB-500, MOTS-c, Semax, Epitalon and KPV.
If HHS listens, you won't be able to get them from a real pharmacy with a doctor's prescription. Only the gray market.
And people are going to find a way to get peptides either way. All this letter decides is whether the guy buying BPC-157 gets it from a pharmacy or gray market.
I'm not telling you the gray market is the answer. Testing, sterility, purity, etc. all of it matters.
So if they really cared about your safety, they'd want him at the pharmacy.
The truth is, your health was never in their best interest. These guys don't really care about you.
5
266
Rat retweeted
2022 is widely acknowledged as a bear market, but notice how the net flow Z-score has surpassed 2022 levels multiple times in the past 4 years and has come close to it even more times.
We've been in a bear market since 2022.
The AI bull market hasn't even started.
Rat retweeted
$HIMS bears on X: “Hims launched peptides without even having peptides.” 😭
I think people are overlooking the strategic reasoning behind the Peptides+ launch.
There’s a massive difference between operating an independent longevity clinic and running a publicly traded healthcare platform serving millions of customers.
Sermorelin has a history of FDA approval. Ipamorelin doesn’t.
Considering everything Hims has experienced with GLP-1 regulatory challenges, is it really surprising that management might prioritize regulatory compliance over an aggressive initial rollout?
Moreover, Hims has already announced plans to introduce BPC-157 and TB-500, subject to regulatory developments.
The company isn’t just selling peptides. It’s building an integrated healthcare ecosystem encompassing:
• Peptides and longevity treatments
• Blood testing
• Hormonal health
• Personalized prescriptions
• Ongoing clinical care
Clinical criticism is absolutely welcome, but expecting a publicly traded healthcare company to introduce every experimental peptide on DAY ONE is unrealistic.
Enter the market. Establish the infrastructure. Expand the portfolio as regulatory clarity improves. Scale.
This is a product launch, not the finished product.
The bigger picture matters. $HIMS 🐂
Rat retweeted
To be honest with you, I had no idea the modern stock market would test how much of a retarded pussy we all are individually at this level of intensity and practically several times per month
Luckily, we have the right framework to respond and cooperate
Rat retweeted
Former Netflix CFO and current $HIMS Lead Independent Director David B. Wells continues to strengthen his position in Hims & Hers.
His shareholding journey:
• Before May 26: 176,017 shares
• May 26: 224,417 shares
• June: 228,073 shares
• November: 230,859 shares
That’s a 31.16% increase in ownership in less than six months.
He invested $1.17M of his own money in May, purchasing 48,400 shares at an average price of $24.235.
Despite the massive sell-off:
• Zero reported shares sold since the purchase.
• ~$4.01M in total holdings at $17.37/share.
• Continues to receive equity instead of cash director compensation.
Insider conviction is worth paying attention to, especially when it comes from someone who chairs the company’s Audit Committee.
$HIMS
Source: SEC Form 4 filings.
🤖 Made with AI
Rat retweeted
when you define healthcare as more than just medication, you invite more people to find their own version of health.
kudos to the entire uk team!
For many women, calories in, calories out doesn’t add up. Today, women in the UK can add more support from Hers Weight Loss, including:
• Hers Metabolic Deep Dive. A free, 10-minute look at 100+ factors that could be making weight loss harder.
• Hers Metabolic Health Test. An optional at-home blood test covering 24 markers, including cholesterol, HbA1c, and thyroid checks, plus hormones, inflammation, and markers linked to insulin resistance.
• Care+. Extra support alongside a Hers weight loss plan, designed by women’s health experts.
Read more: news.hims.com/newsroom/hers-…
Rat retweeted
$HIMS revenue is up a lot since 2020
The stock not so much
Rat retweeted
$HIMS Peptides+ is here-
“Sermorelin, NAD+, Glutathione, Vitamin B12, and L-Carnitine, depending on their needs as determined by their provider (now available). Access to BPC-157 and TB-500 will follow, consistent with regulatory standards.”
More than 10,000 people signed up for early access when we launched the waitlist two weeks ago for Peptides+. Starting today, they all have access to a comprehensive intake that will be the beginning of a journey with a provider to find whether a personalized treatment plan is right for them.
Clinically-guided protocols. At-home blood collection. The full support of a care team that knows you, your progress, and your goals. And 5 US-compounded treatments, with more to come soon.
It’s exactly what we think health should be: easy, personal, high-quality, supported by independent experts, and on the cutting edge of where science is going.
We can’t wait to see where those journeys take you.
Read more here, including important info: investors.hims.com/news/news…
$HIMS figured out how to get existing members to pay more (massive ARPU increase)
And you are besrish?
Retards
7
372
Rat retweeted
[read about what’s happening with AI]
ME: Wow we’re actually legit fucked this is so bad.
[go outside]
ME: Wait those people are all acting like nothing unusual is happening. Maybe I was just in a paranoid bubble? Yeah it must be that. Phew.
[read more about what’s happening with AI]
ME: Wait no we ARE fucked. Shit. It’s all those people outside who are in a delusional bubble.
[go outside]
ME: Wait...






















